18F-FDG PET-CT评价淋巴瘤骨髓浸润的临床价值

doi:10.3760/cma.j.issn.1673422X.2016.08.019

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (8): 634-637.doi: 10.3760/cma.j.issn.1673422X.2016.08.019

¹⁸F-FDG PET-CT评价淋巴瘤骨髓浸润的临床价值

吴媛,刘小兰,苏丽萍

030013 太原，山西医科大学附属肿瘤医院血液科

出版日期:2016-08-08 发布日期:2016-07-05
通讯作者: 苏丽萍，Email： sulp2005@sohu.com E-mail:sulp2005@sohu.com
基金资助:
山西省卫生厅科技攻关计划（2011044）

The clinical utility of 18F-FDG PET-CT for detection of bone marrow infiltration in lymphoma

Wu Yuan, Liu Xiaolan, Su Liping

Department of Hematology, Shanxi Medical University Affliated Tumor Hospital, Taiyuan 030013, China

Online:2016-08-08 Published:2016-07-05
Contact: Su Liping， Email： sulp2005@sohu.com E-mail:sulp2005@sohu.com
Supported by:
Program for Science and Technology Development of Shanxi Provincial Department of Health（2011044）

摘要/Abstract

摘要： 淋巴瘤骨髓浸润对疾病的诊断、分期、治疗方案选择及预后评估至关重要，常规部位的骨髓活检为主要检测手段，但假阴性率高。18氟脱氧葡萄糖-正电子发射计算机断层显像（18F-FDG PET-CT）将形态学与功能代谢整合在一起，具有高敏感性、高特异性及功能显像的优点，18F-FDG PET-CT为淋巴瘤骨髓浸润的诊断、疾病分期及预后评估提供了新的途径。

关键词: 淋巴瘤, 骨髓, 氟脱氧葡萄糖F18, 正电子发射断层显像术

Abstract: Bone marrow infiltration in lymphoma is crucial to the disease diagnosis, staging, treatment options and prognostic evaluation. Although bone marrow biopsy is the main detecting method, it has high false negative rate. At present, 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) technology which is integrating morphological characteristics with metabolic function provides a new way for the diagnosis, staging and prognostic evaluation of bone marrow infiltration in lymphoma due to its advantages of high sensitivity, high specificity and functional image.

Key words: ymphoma, Bone marrow, Fluod deoxyglucose F18, Positronemission tomography

吴媛,刘小兰,苏丽萍. ¹⁸F-FDG PET-CT评价淋巴瘤骨髓浸润的临床价值[J]. 国际肿瘤学杂志, 2016, 43(8): 634-637.

Wu Yuan, Liu Xiaolan, Su Liping. The clinical utility of 18F-FDG PET-CT for detection of bone marrow infiltration in lymphoma[J]. Journal of International Oncology, 2016, 43(8): 634-637.

参考文献

［1］ El-Galaly TC, D′amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomographystaged treatmentnaive patients with hodgkin lymphoma［J］. J Clin Oncol, 2012, 30(36): 4508-4514. DOI: 10.1200/JCO.2012.42.4036. ［2］ Hutchings M. The role of bone marrow biopsy in hodgkin lymphoma staging: "to be, or not to be, that is the question"?［J］. Leuk Lymphoma, 2012, 53(4): 523-524. DOI: 10.3109/10428194.2012.659737. ［3］ Alavi A, Shrikanthan S, Aydin A, et al. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma［J］. Clin Lymphoma Myeloma Leuk, 2011, 11(3): 261-266. DOI: 10.1016/j.clml.2011.03.013. ［4］ Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lymphoma［J］. Eur J Nucl Med Mol Imaging, 2014, 41(5): 1004-1027. DOI: 10.1007/s00259-013-2686-2. ［5］ Muzahir S, Mian M, Munir I, et al. Clinical utility of 18F FDG-PET/CT in the detection of bone marrow disease in hodgkin′s lymphoma［J］. Br J Radiol, 2012, 85(116): e490-496. DOI: 10.1259/bjr/29583493. ［6］汤日杰, 桂思, 李建生, 等. 18F-FDG PET/CT与大范围弥散磁共振成像评价非霍奇金淋巴瘤骨髓浸润的对比研究［J］. 中华血液学杂志, 2014, 35(3): 231-235. DOI: 10.3760/cma.j.issn.0253-2727.2014.03.011. ［7］ Adams HJ, Kwee TC, Vermoolen MA, et al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET［J］. Eur Radiol, 2013, 23(8): 2271-2278. DOI: 10.1007/s00330-013-2835-9. ［8］ Casulo C, Sch-der H, Feeney J, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma［J］. Leuk Lymphoma, 2013, 54(10): 2163-2167. DOI: 10.3109/10428194.2013.767901. ［9］ Adams HJ, Kwee TC, De Keizer B, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed hodgkin lymphoma: is bone marrow biopsy still necessary?［J］. Ann Oncol, 2014, 25(5): 921-927. DOI: 10.1093/annonc/mdt533. ［10］ Adams HJ, Kwee TC, De Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and metaanalysis［J］. Eur J Nucl Med Mol Imaging, 2014, 41(3): 565-574. DOI: 10.1007/s00259-013-2623-4. ［11］ Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis［J］. J Nucl Med, 2005, 46(6): 958-963. ［12］ Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate［J］. Eur J Nucl Med Mol Imaging, 2009, 36(5): 745-750. DOI: 10.1007/s00259-008-1021-9. ［13］ Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP［J］. J Clin Oncol, 2011, 29(11): 1452-1457. DOI: 10.1200/JCO.2010.33.3419. ［14］ Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement［J］. Blood, 2013, 122(1): 61-67. DOI: 10.1182/blood-2012-12-473389. ［15］ Wu X, Pertovaara H, Korkola P, et al. Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma［J］. PLoS One, 2014, 9(1): e84999. DOI: 10.1371/journal.pone.0084999. ［16］ Takahashi T, Minato M, Tsukuda H, et al. Successful treatment of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy and FDG-PET scan［J］. Intern Med, 2008, 47(10): 975-979. ［17］ Pelosi E, Penna D, Deandreis D, et al. FDG-PET in the detection of bone marrow disease in hodgkin′s disease and aggressive non-hodgkin′s lymphoma and its impact on clinical management［J］. Eur J Nucl Med Mol Imaging, 2008, 52(1): 9-16. ［18］ Weiler-Sagie M, Kagna O, Dann EJ, et al. Characterizing bone marrow involvement in hodgkin′s lymphoma by FDG-PET/CT［J］. Eur J Nucl Med Mol Imaging, 2014, 41(6): 1133-1140. DOI: 10.1007/s00259-014-2706-x. ［19］乔文礼, 赵晋华, 王椿, 等. 18F-FDG符合探测显像与CT显像在淋巴瘤分期和疗效评价中的比较［J］. 中华肿瘤杂志, 2007, 29(7): 536-539. DOI: 10.3760/j.issn:02533766.2007.07.014. ［20］ Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy［J］. J Nucl Med, 2013, 54(8): 1244-1250. DOI: 10.2967/jnumed.112.114710.

[1]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[2]	任露, 谢晓丽, 张坤, 王丽娟. 双氢青蒿素联合卡非佐米对多发性骨髓瘤细胞活性、增殖、凋亡的影响及机制研究[J]. 国际肿瘤学杂志, 2024, 51(3): 129-136.
[3]	张雨潇, 张连生, 李莉娟. 新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景[J]. 国际肿瘤学杂志, 2023, 50(2): 122-125.
[4]	孙琦, 李文倩, 解友邦, 周厚法. 化疗后骨髓抑制机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 33-36.
[5]	赵建昊, 段衍超. 多发性骨髓瘤髓外病变发病机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 55-59.
[6]	殷运燕, 李慧, 李雨晨, 惠慧, 许景艳. 组蛋白去乙酰化酶抑制剂在非霍奇金淋巴瘤中的临床应用[J]. 国际肿瘤学杂志, 2022, 49(8): 499-504.
[7]	王柳雪, 席晓平, 刘静静, 沈国民, 杨海平. 二甲双胍在非霍奇金淋巴瘤中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 436-440.
[8]	高珊, 陆敏秋, 石磊, 褚彬, 房立娟, 项秋晴, 王宇彤, 丁月华, 鲍立. 伊沙佐米联合方案治疗复发/难治多发性骨髓瘤的疗效和安全性分析[J]. 国际肿瘤学杂志, 2022, 49(5): 286-291.
[9]	孙淑琴, 钱秋红, 张友忠. 盆腔原发弥漫性大B细胞淋巴瘤1例[J]. 国际肿瘤学杂志, 2022, 49(5): 319-320.
[10]	郭奕维, 刘爱春. EB病毒阳性弥漫大B细胞淋巴瘤的治疗[J]. 国际肿瘤学杂志, 2021, 48(7): 385-388.
[11]	孙睿婕, 单宁宁. 复发难治性多发性骨髓瘤的免疫靶向治疗及存在的问题[J]. 国际肿瘤学杂志, 2021, 48(6): 381-384.
[12]	申加兴, 张珊, 陈祥静, 王丽, 孙晓艳, 吕衍民, 宋冠华, 姚成芳. TGF-β诱导肺脏癌相关成纤维细胞高表达IL-17D并促进MDSC募集[J]. 国际肿瘤学杂志, 2021, 48(5): 275-281.
[13]	李巧佴, 邹立群. 老年弥漫大B细胞淋巴瘤的分层治疗策略[J]. 国际肿瘤学杂志, 2021, 48(5): 317-320.
[14]	陈曦, 母丹, 严钦, 刘文君. 骨髓微环境与白血病细胞分化[J]. 国际肿瘤学杂志, 2021, 48(3): 189-192.
[15]	乔薇, 宋腾, 陈馨蕊, 王华庆. PI3K信号通路过度激活对非霍奇金淋巴瘤患者预后的影响及其靶向药物疗效[J]. 国际肿瘤学杂志, 2021, 48(2): 121-124.

¹⁸F-FDG PET-CT评价淋巴瘤骨髓浸润的临床价值

The clinical utility of 18F-FDG PET-CT for detection of bone marrow infiltration in lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价